viewValiRx PLC

ValiRx Plc celebrating 'particularly important' European patent

ValiRx Plc (LON:VAL) shares rose as it strengthened its worldwide patent protection for lead drug VAL 201 - having been granted a patent by the European office.

Chief operating officer Dr George Morris tells Proactive: ''It's always gratifying to have granted patents rather than just pending patents.''

''On this occasion I think it's particularly important in that all the key markets in which we are currently doing work and are likely to be doing work are now protected and covered for the use and the cancer therapy applications of VAL 201''.

Quick facts: ValiRx PLC

Price: 6.75 GBX

Market: AIM
Market Cap: £2.43 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...



Investor Update: Green light for ValiRx to increase dose of VAL201

Top stories from the Proactive Investors UK newsroom. ValirX (LON:VAL) has received a boost for its prostate cancer treatment VAL201 after UK regulators approved a substantial increase in the doses allowed in future clinical trials. The phase I/II trial so far has met all primary and...

on 20/6/19

2 min read